This combination IV infusion is indicated for:
Ceftazidime acts by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), resulting in bacterial cell lysis and death. Avibactam is a non-β-lactam β-lactamase inhibitor that forms a stable covalent bond with β-lactamase enzymes and resists hydrolysis. It inhibits Ambler class A enzymes, class C β-lactamases, and some class D enzymes, including extended-spectrum β-lactamases (ESBLs), KPC, OXA-48 carbapenemases, and AmpC enzymes. However, it does not inhibit class B enzymes (metallo-β-lactamases) and has limited activity against some class D enzymes.
Dosage in Adult Patients with Creatinine Clearance (CrCl) greater than 50 mL/min
| Infection | Dose | Frequency | Infusion Time | Duration of Treatment |
|---|---|---|---|---|
| Complicated Intra-abdominal Infections [used in combination with metronidazole] (cIAI) | 2.5 grams | Every 8 hours | 2 hours | cIAI: 5 to 14 days |
| Complicated Urinary Tract Infections including Pyelonephritis (cUTI) | 2.5 grams | Every 8 hours | 2 hours | cUTI: 7 to 14 days |
| Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) | 2.5 grams | Every 8 hours | 2 hours | HABP/VABP: 7 to 14 days |
Dosage in Adult Patients with Creatinine Clearance (CrCl) less than 50 mL/min
| Estimated CrCl (mL/minute) | Dose | Frequency |
|---|---|---|
| 31 to 50 | 1.25 grams (ceftazidime 1 gram and avibactam 0.25 grams) intravenously | Every 8 hours |
| 16 to 30 | 0.94 grams (ceftazidime 0.75 grams and avibactam 0.19 grams) intravenously | Every 12 hours |
| 6 to 15 | 0.94 grams (ceftazidime 0.75 grams and avibactam 0.19 grams) intravenously | Every 24 hours |
| Less than or equal to 5 | 0.94 grams (ceftazidime 0.75 grams and avibactam 0.19 grams) intravenously | Every 48 hours |
Dosage in Patients 3 months to <18 years
| Infection | Age Range | Dose | Frequency | Infusion Time | Duration of Treatment |
|---|---|---|---|---|---|
| cIAI and cUTI including Pyelonephritis | 2 years to less than 18 years | 62.5 mg/kg to a maximum of 2.5 grams (Ceftazidime 50 mg/kg and avibactam 12.5 mg/kg to a maximum dose of ceftazidime 2 grams and avibactam 0.5 grams) | Every 8 hours | 2 Hours | cIAI: 5 to 14 days |
| 6 months to less than 2 years | 62.5 mg/kg (Ceftazidime 50 mg/kg and avibactam 12.5 mg/kg) | Every 8 hours | 2 Hours | cUTI: 7 to 14 days | |
| 3 months to less than 6 months | 50 mg/kg (Ceftazidime 40 mg/kg and avibactam 10 mg/kg) | Every 8 hours | 2 Hours | — |
In Pediatric Patients 2 to <18 years with Renal Impairment
| Estimated eGFR (mL/min/1.73m²) | Dose | Frequency |
|---|---|---|
| 31 to 50 | 31.25 mg/kg to a maximum of 1.25 grams (Ceftazidime 25 mg/kg and avibactam 6.25 mg/kg to a maximum dose of ceftazidime 1 gram and avibactam 0.25 grams) | Every 8 hours |
| 16 to 30 | 23.75 mg/kg to a maximum of 0.94 grams (Ceftazidime 19 mg/kg and avibactam 4.75 mg/kg to a maximum dose of ceftazidime 0.75 grams and avibactam 0.19 grams) | Every 12 hours |
| 6 to 15 | 23.75 mg/kg to a maximum of 0.94 grams (Ceftazidime 19 mg/kg and avibactam 4.75 mg/kg) | Every 24 hours |
| Less than or equal to 5 | 23.75 mg/kg to a maximum of 0.94 grams (Ceftazidime 19 mg/kg and avibactam 4.75 mg/kg) | Every 48 hours |
Clinical interaction studies with this IV infusion or avibactam alone in combination with probenecid have not been conducted. Therefore, concomitant use of this IV infusion with probenecid is not recommended.
This combination is contraindicated in patients with known severe hypersensitivity to ceftazidime, avibactam, other avibactam-containing products, or any member of the cephalosporin class.
Adult cIAI, cUTI, and HABP/VABP patients: The most frequently reported adverse effects include diarrhea, nausea, and vomiting.
cUTI patients: Common adverse reactions (≥3%) include diarrhea and nausea.
HABP/VABP patients: Common adverse effects (≥5%) include diarrhea and vomiting.
Pediatric cIAI and cUTI patients: Frequently reported reactions (≥3%) include vomiting, diarrhea, rash, and infusion site phlebitis.
There are no adequate and well-controlled studies of this IV infusion, ceftazidime, or avibactam in pregnant women. Additionally, there is no available information regarding their effects on breastfed infants or milk production.
Reduced clinical response has been observed in adult cIAI patients with baseline creatinine clearance (CrCl) between 30 to ≤50 mL/min. Renal function should be monitored daily in both adult and pediatric patients, and dosage adjustments should be made accordingly.
Hypersensitivity reactions, including anaphylaxis and severe skin reactions, may occur. Cross-reactivity may be seen in patients with a history of penicillin allergy. If allergic reactions develop, discontinue the drug immediately.
Clostridioides difficile-associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including this IV infusion. Patients presenting with diarrhea should be evaluated carefully.
Central nervous system effects, including seizures and other neurologic reactions, may occur, especially in patients with renal impairment. Dose adjustment is necessary in such cases.
Store at a temperature not exceeding 25°C in a dry place. Protect from light and moisture.
What is Ceftazidime + Avibactam for?
What does Ceftazidime + Avibactam do?
What are the side effects of Ceftazidime + Avibactam?
What happens if you take too much Ceftazidime + Avibactam?
Can Ceftazidime + Avibactam be taken during pregnancy?
No available drugs found